<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of islet <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> in the <z:hpo ids='HP_0003674'>onset</z:hpo> and progression of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> remains obscure </plain></SENT>
<SENT sid="1" pm="."><plain>Islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> is a 37 amino-acid, beta-cell <z:chebi fb="7" ids="16670">peptide</z:chebi> which is co-stored and co-released with insulin </plain></SENT>
<SENT sid="2" pm="."><plain>Human islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> refolds to a beta-conformation and oligomerises to form insoluble fibrils; proline substitutions in rodent islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> prevent this molecular transition </plain></SENT>
<SENT sid="3" pm="."><plain>Pro-islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (67 amino acids in man) is processed in secretory granules </plain></SENT>
<SENT sid="4" pm="."><plain>Refolding of islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> may be prevented by intragranular heterodimer formation with insulin (but not proinsulin) </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp>-associated abnormal proinsulin processing could contribute to de-stabilisation of granular islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Increased pro-islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> secretion as a consequence of islet dysfunction could promote fibrillogenesis; the propeptide forms fibrils and binds to basement membrane glycosamino-<z:chebi fb="0" ids="18154">glycans</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> gene polymorphisms are not universally associated with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Transgenic mice expressing human islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> gene have increased islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> concentrations but develop islet amyloid only against a background of <z:hpo ids='HP_0001513'>obesity</z:hpo> and/or high fat diet </plain></SENT>
<SENT sid="9" pm="."><plain>In transgenic mice, <z:mp ids='MP_0001261'>obese</z:mp> monkeys and cats, initially small perivascular deposits progressively increase to occupy 80% islet mass; the severity of <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> in animal models is related to the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, suggesting that islet amyloid and the associated destruction of islet cells cause <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>In human <z:mp ids='MP_0002055'>diabetes</z:mp>, islet amyloid can affect less than 1% or up to 80% of islets indicating that islet <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> largely results from <z:mp ids='MP_0002055'>diabetes</z:mp>-related pathologies and is not an aetiological factor for <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>However, the associated progressive beta-cell destruction leads to severe islet dysfunction and insulin requirement </plain></SENT>
</text></document>